| 0.087 0 (0%) | 04-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.33 | 1-year : | 0.54 |
| Resists | First : | 0.28 | Second : | 0.46 |
| Pivot price | 0.01  |
|||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0 |
MA(20) : | 0.04 |
| MA(100) : | 0.16 |
MA(250) : | 0.88 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7.2 |
D(3) : | 5.5 |
| RSI | RSI(14): 37.6 |
|||
| 52-week | High : | 3.13 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PLXP ] has closed above bottom band by 17.7%. Bollinger Bands are 83.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.01 - 0.01 | 0.01 - 0.01 |
| Low: | 0.01 - 0.01 | 0.01 - 0.01 |
| Close: | 0.01 - 0.01 | 0.01 - 0.01 |
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.
Sat, 06 Apr 2024
PLx Pharma Looks At Alternatives As Vazalore Faces Macro Headwinds - AOL
Wed, 12 Apr 2023
Why Is PLx Pharma (PLXP) Stock Down 32% Today? - InvestorPlace
Wed, 12 Apr 2023
PLx Pharma intends to file for bankruptcy, inks stalking horse deal; stock +9% after hours - Seeking Alpha
Tue, 11 Apr 2023
Why Is Virgin Orbit (VORB) Stock Down 27% Today? - InvestorPlace
Tue, 11 Apr 2023
Why Is PLx Pharma (PLXP) Stock Down 38% Today? - InvestorPlace
Fri, 12 Aug 2022
Spectrum Brands (SPB) Q3 Earnings and Revenues Lag Estimates - Zacks Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 2.525e+007 (%) |
| Held by Institutions | 15.3 (%) |
| Shares Short | 142 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.431e+007 |
| EPS Est Next Qtrly | -0.47 |
| EPS Est This Year | -1.62 |
| EPS Est Next Year | -1.83 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 417.7 % |
| Return on Equity (ttm) | -64.4 % |
| Qtrly Rev. Growth | 4.54e+006 % |
| Gross Profit (p.s.) | -24.04 |
| Sales Per Share | -19.18 |
| EBITDA (p.s.) | 867347 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -59 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.06 |
| Dividend | 0 |
| Forward Dividend | 246170 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2017-04-19 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|